Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
REVERCE II
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
- NCT04117945 ↗
- Unknown
- Academic and Community Cancer Research United
- Focused
We haven't built an HCP commentary report on REVERCE II yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on REVERCE II so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase II Study of Regorafenib Followed by Anti-EGFR Monoclonal Antibody Therapy Versus the Reverse Sequencing for Metastatic Colorectal Cancer Patients Previously Treated With Fluoropyrimidine, Oxaliplatin and Irinotecan (REVERCE II)
- Phase
- Phase 2
- Status
- Unknown
- Conditions
- BRAF V600E Negative; KRAS Gene Mutation Negative; Locally Advanced Unresectable Colorectal Adenocarcinoma; Metastatic Colorectal Adenocarcinoma; NRAS Gene Mutation Negative; Stage III Colorectal Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8
- Interventions
- Cetuximab; Irinotecan; Panitumumab; Regorafenib
- Arms
- Arm A (regorafenib) · Experimental
- Arm B (cetuximab, panitumumab, irinotecan) · Experimental
- Enrollment
- 22
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- Academic and Community Cancer Research United with National Cancer Institute (NCI)
- Start
- Mar 3, 2020
- Primary completion
- Sep 5, 2023
- Results posted
- Yes
- Registry record
- NCT04117945 · updated Sep 27, 2024